Regulus Therapeutics
RGLS
#7340
Rank
A$0.80 B
Marketcap
A$11.68
Share price
0.00%
Change (1 day)
397.39%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -A$72.73 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -A$66.12 Million a decrease over its 2023 earnings that were of -A$42.13 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -A$72.73 Million9.99%
2024 -A$66.12 Million56.97%
2023 -A$42.13 Million6.51%
2022 -A$39.55 Million2.53%
2021 -A$38.57 Million93.59%
2020 -A$19.93 Million-15.41%
2019 -A$23.56 Million-64.46%
2018 -A$66.27 Million-33.26%
2017 -A$99.29 Million-13.98%
2016 -A$0.12 Billion44.77%
2015 -A$79.74 Million-1.63%
2014 -A$81.06 Million203.6%
2013 -A$26.7 Million8.65%
2012 -A$24.58 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
A$10.24 B-15,196.86%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
A$1.44 B-2,232.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$17.04 B-25,211.22%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$20.51 B-30,317.80%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
A$11.29 B-16,734.36%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-A$0.16 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-A$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
A$1.60 B-2,471.21%๐Ÿ‡บ๐Ÿ‡ธ USA